Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors.

Glucocorticoids and their synthetic analogs exert potent antiinflammatory actions that, in most cases, are due to an inhibition of the expression of inflammatory genes. In this study, we elucidated the mechanisms of dexamethasone-mediated suppression of matrix metalloproteinase-9 (MMP-9) expression triggered by IL-1beta in rat mesangial cells. Treatment of mesangial cells with dexamethasone markedly reduced the gelatinolytic content of conditioned media due to a decrease in MMP-9 expression. Cloning of a 1.3-kb fragment of the rat MMP-9 gene promoter and subsequent site- directed mutagenesis revealed that a nuclear factor kappaB (NF-kappaB) site at -561 to -550 and a region from -511 to -497 bearing a distal activator protein 1 site adjacent to an Ets-binding site are essentially involved in the IL-1beta-mediated transactivation of MMP-9. Inhibition of MMP-9 expression by dexamethasone resides in a promoter region downstream of -597. The IL-1beta-caused increase in DNA binding of both NF-kappaB and Ets-1 immunopositive complexes was substantially suppressed by dexamethasone as shown by EMSA. This was paralleled with a reduced abundance of p65 and Ets-1 proteins in cell nuclei concomitantly with a reduced inhibitor of kappaB (IkappaB) degradation. In addition to NF-kappaB, we suggest a pivotal role for the Ets binding site, in concert with a distal activator protein-1 element, in the transcriptional suppression of cytokine-induced MMP-9 expression by glucocorticoids.

[1]  N. Bhat,et al.  Physical Interaction and Functional Synergy between Glucocorticoid Receptor and Ets2 Proteins for Transcription Activation of the Rat Cytochrome P-450c27 Promoter* , 2001, The Journal of Biological Chemistry.

[2]  P. Herrlich.  Cross-talk between glucocorticoid receptor and AP-1 , 2001, Oncogene.

[3]  H. Mühl,et al.  Regulation of interleukin-18 (IL-18) expression in keratinocytes (HaCaT): implications for early wound healing. , 2000, European cytokine network.

[4]  J. Pfeilschifter,et al.  Amplification of IL-1β-Induced Matrix Metalloproteinase-9 Expression by Superoxide in Rat Glomerular Mesangial Cells Is Mediated by Increased Activities of NF-κB and Activating Protein-1 and Involves Activation of the Mitogen-Activated Protein Kinase Pathways1 , 2000, The Journal of Immunology.

[5]  M. Fresno,et al.  Tumor Necrosis Factor-α Activation of NF-κB Requires the Phosphorylation of Ser-471 in the Transactivation Domain of c-Rel* , 2000, The Journal of Biological Chemistry.

[6]  G. Davies-Jones,et al.  Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. , 2000, Brain : a journal of neurology.

[7]  J. Pfeilschifter,et al.  Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells. , 2000, Kidney international.

[8]  J. Bousquet,et al.  Tissue inhibitor of metalloproteinase-1 levels in bronchoalveolar lavage fluid from asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.

[9]  A. Harf,et al.  Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. , 1999, American journal of respiratory cell and molecular biology.

[10]  J. Pfeilschifter,et al.  Potentiation of nitric oxide synthase expression by superoxide in interleukin 1β‐stimulated rat mesangial cells , 1998, FEBS letters.

[11]  S. Werner,et al.  Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. , 1998, Experimental cell research.

[12]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[13]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[14]  P. Herrlich,et al.  Transcriptional cross-talk, the second mode of steroid hormone receptor action , 1998, Journal of Molecular Medicine.

[15]  J. Pfeilschifter,et al.  Molecular mechanisms of inducible nitric oxide synthase gene expression by IL-1beta and cAMP in rat mesangial cells. , 1998, Journal of immunology.

[16]  H. Chung,et al.  Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells , 1998, Oncogene.

[17]  H. Klocker,et al.  Androgen Receptor-Ets Protein Interaction Is a Novel Mechanism for Steroid Hormone-mediated Down-modulation of Matrix Metalloproteinase Expression* , 1996, The Journal of Biological Chemistry.

[18]  E. Lengyel,et al.  Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences (*) , 1996, The Journal of Biological Chemistry.

[19]  R. Evans,et al.  Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor , 1996, Steroids.

[20]  T. Salo,et al.  Effects of Dexamethasone and Cell Proliferation on the Expression of Matrix Metalloproteinases in Human Mucosal Normal and Malignant Cells , 1996, Journal of dental research.

[21]  Z. Werb,et al.  Synergistic Transcriptional Activation of the Tissue Inhibitor of Metalloproteinases-1 Promoter via Functional Interaction of AP-1 and Ets-1 Transcription Factors (*) , 1996, The Journal of Biological Chemistry.

[22]  J. Pfeilschifter,et al.  Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Mühl,et al.  THERAPEUTIC STRATEGIES FOR THE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE—POTENTIAL FOR A NOVEL CLASS OF ANTI‐INFLAMMATORY AGENTS , 1996, Cell biology international.

[24]  横尾隆.  Dual regulation of IL-1β-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-κB and AP-1(インターロイキンー1β刺激下でのメサンギウム細胞の細胞外基質分解酵素-9の発現: 転写因子) , 1996 .

[25]  M. Kitamura,et al.  Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. , 1996, The American journal of physiology.

[26]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[27]  T. Noumi,et al.  Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. , 1995, Oncogene.

[28]  J A Gustafsson,et al.  Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. , 1995, Molecular endocrinology.

[29]  M. Matsubara,et al.  The rabbit gene for 92-kDa matrix metalloproteinase. Role of AP1 and AP2 in cell type-specific transcription. , 1994, The Journal of biological chemistry.

[30]  R. Pictet,et al.  Participation of Ets transcription factors in the glucocorticoid response of the rat tyrosine aminotransferase gene , 1994, Molecular and cellular biology.

[31]  W. Couser,et al.  Role of oxidants and proteases in glomerular injury. , 1994, Kidney international.

[32]  H. Sato,et al.  v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. , 1993, The Journal of biological chemistry.

[33]  T. Salo,et al.  Demonstration of 72-kDa and 92-kDa forms of type IV collagenase in human skin: variable expression in various blistering diseases, induction during re-epithelialization, and decrease by topical glucocorticoids. , 1993, The Journal of investigative dermatology.

[34]  W C Greene,et al.  NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. , 1993, Science.

[35]  H. Sato,et al.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. , 1993, Oncogene.

[36]  B. Wasylyk,et al.  The Ets family of transcription factors. , 1993, European journal of biochemistry.

[37]  R. Treisman,et al.  Spatial flexibility in ternary complexes between SRF and its accessory proteins. , 1992, The EMBO journal.

[38]  P. Verde,et al.  A regulatory element that mediates co‐operation between a PEA3‐AP‐1 element and an AP‐1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. , 1992, The EMBO journal.

[39]  D. Lovett,et al.  Proteinases and glomerular matrix turnover. , 1992, Kidney international.

[40]  B. Wasylyk,et al.  The c‐Ets oncoprotein activates the stromelysin promoter through the same elements as several non‐nuclear oncoproteins. , 1991, The EMBO journal.

[41]  B. Wasylyk,et al.  The collagenase gene promoter contains a TPA and oncogene‐responsive unit encompassing the PEA3 and AP‐1 binding sites. , 1990, The EMBO journal.